Kazia

KZIA NASDAQ
2.639
-0.091
-3.33%
已收盘, 16:00 06/17 EDT
开盘
2.700
昨收
2.730
最高
2.700
最低
2.590
成交量
5,659
成交均量(3M)
3,626
52周最高
4.810
52周最低
2.040
换手率
0.09%
市值
1,640.58万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Kazia KZIA股票价格,Kazia股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
展开 >

最近浏览

名称
价格
涨跌幅